Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Dose-Escalated Magnetic Resonance Image–Guided Abdominopelvic Reirradiation With Continuous Intrafraction Visualization, Soft Tissue Tracking, and Automatic Beam Gating

“…Grade 3+ toxicity was felt to be acceptable (34%) and patients who were able to undergo subsequent surgery had especially promising LC and OS. In addition to locally recurrent rectal cancer, reRT is also feasible for anal canal, gynecologic, prostate, and other abdominopelvic cancers (7,(20)(21)(22).…”

“…In addition to locally recurrent rectal cancer, reRT is also feasible for anal canal, gynecologic, prostate, and other abdominopelvic cancers. 7 , 20 , 21 , 22 …”

Successful Stereotactic Body Radiation Therapy for Postbrachytherapy Prostate Recurrence and Penile Bulb Metastasis

“…The cumulative dose to the bulbomembranous urethra that leads to an unacceptable risk of stricture in the post-brachytherapy retreatment setting is unknown, and estimation is complicated by the inconsistent inclusion of the penile bulb in post implant dosimetry reporting (22) and the challenges of combining doses in a biologically relevant fashion from two distinct treatment modalities. A majority of published reirradiation studies include dose constraints relating only to the retreatment, irrespective of cumulative dose or the primary treatment modality (23). Thus, a specific cumulative dose goal for the bulbomembranous urethra or penile bulb SBRT after prior brachytherapy cannot currently be recommended.…”

“…Penile bulb dose constraints in SBRT retreatment trials with favorable toxicity rates have included V 29.5Gy < 50% and V 24Gy < 50%, whereas urethral dose constraints are less conservative (ie. D median <31 Gy), likely owing to the course of the urethra through the target volume (prostate) (23).…”

Radiation therapy for prostate cancer: What’s the best in 2021

“…96 Besides ablative treatments, great interest is addressed on the potential applications of MRgRT in the field of prostate cancer recurrences re-treatment, due to the favorable toxicity profile that seems to be correlated with this technology. 97 Thanks to the promising first results, different studies with the purpose of investigating acute toxicity and MRgSBRT safety and performance have recently been launched, such as the MIRAGE trial-NCT04384770 98 ; the PRISM study-NCT03658525 (ClinicalTrials.gov., https://clinicaltrials.gov/ct2/show/NCT03658525); or the MOMENTUM study-NCT04075305 (https://clinicaltrials.gov/ct2/show/NCT04075305).…”